Abstract
Mucopolysaccharosis III (MPS III) is a lysosomal storage disorder and belongs to the group of mucopolysaccharidoses. MPS III is caused by a deficiency of one of the four enzymes catalyzing the degradation of the glycosaminoglycan heparan sulfate. MPS III is clinically characterized by progressive dementia with distinct behavioral disturbances and relatively mild somatic disease. This review will summarize and discuss the available and potential future therapeutic options for patients with MPS III. This includes enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), substrate reduction therapy (SRT), chaperone-mediated therapy, and gene therapy. Although clinical efficacy has not yet been fully demonstrated for any of these therapies, it is likely that future developments will lead to disease- modifying treatment for this devastating disease.
Keywords: Enzyme replacement therapy, gene therapy, hematopoietic stem cell transplantation, mucopolysaccharidosis iii, sanfilippo syndrome, substrate reduction therapy, lysosomal storage disorder, glycosaminoglycan heparan sulfate, behavioral disturbances, hematopoietic stem cell transplantation (HSCT), chaperone-mediated therapy, disease-modifying treatmen, autosomal recessive inherited deficiency
Current Pharmaceutical Biotechnology
Title: Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies
Volume: 12 Issue: 6
Author(s): J. de Ruijter, M. J. Valstar and F. A. Wijburg
Affiliation:
Keywords: Enzyme replacement therapy, gene therapy, hematopoietic stem cell transplantation, mucopolysaccharidosis iii, sanfilippo syndrome, substrate reduction therapy, lysosomal storage disorder, glycosaminoglycan heparan sulfate, behavioral disturbances, hematopoietic stem cell transplantation (HSCT), chaperone-mediated therapy, disease-modifying treatmen, autosomal recessive inherited deficiency
Abstract: Mucopolysaccharosis III (MPS III) is a lysosomal storage disorder and belongs to the group of mucopolysaccharidoses. MPS III is caused by a deficiency of one of the four enzymes catalyzing the degradation of the glycosaminoglycan heparan sulfate. MPS III is clinically characterized by progressive dementia with distinct behavioral disturbances and relatively mild somatic disease. This review will summarize and discuss the available and potential future therapeutic options for patients with MPS III. This includes enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), substrate reduction therapy (SRT), chaperone-mediated therapy, and gene therapy. Although clinical efficacy has not yet been fully demonstrated for any of these therapies, it is likely that future developments will lead to disease- modifying treatment for this devastating disease.
Export Options
About this article
Cite this article as:
de Ruijter J., J. Valstar M. and A. Wijburg F., Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies, Current Pharmaceutical Biotechnology 2011; 12 (6) . https://dx.doi.org/10.2174/138920111795542651
DOI https://dx.doi.org/10.2174/138920111795542651 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?
Current Medicinal Chemistry Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy Covid-19 Susceptibility and Severity Might be Modified by Vitamin D Status: Theoretical and Practical Considerations
Current Respiratory Medicine Reviews Metals and Parkinson's Disease: Mechanisms and Biochemical Processes
Current Medicinal Chemistry Fish Oil Prevents Oxidative Stress and Exerts Sustained Antiamnesic Effect After Global Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease
Current Vascular Pharmacology Changing the Course of Alzheimers Disease: Emerging Disease Modifying Therapies
Current Psychiatry Reviews Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Current Pharmaceutical Design Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Lipid-Based Diets Improve Muscarinic Neurotransmission in the Hippocampus of Transgenic APPswe/PS1dE9 Mice
Current Alzheimer Research Mild Cognitive Impairment (MCI) - The Novel Trend of Targeting Alzheimers Disease in Its Early Stages - Methodological Considerations
Current Alzheimer Research Association of SORL1 Gene Variants with Hippocampal and Cerebral Atrophy and Alzheimer's Disease
Current Alzheimer Research Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes
Current Neurovascular Research Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research